Replimune Group (NASDAQ:REPL) Shares Up 5.2% - What's Next?

Key Points

• Replimune shares rose 5.2% to about $15.40, though trading volume was 90% below the average. The stock has climbed well above its 50-day and 200-day moving averages.
• Analyst sentiment improved, with BMO, Piper Sandler, JPMorgan, and Wedbush issuing upgrades or higher targets. The stock has a consensus “Moderate Buy” rating, although the consensus price target of $11.86 is below its current price.
• The company reported a quarterly loss of $0.72 per share, missing estimates by $0.03. Insiders sold 81,868 shares worth approximately $1.02 million over the past three months, while institutional investors own 92.53% of the stock.

Replimune Group, Inc. (NASDAQ:REPL - Get Free Report) shot up 5.2% during mid-day trading on Tuesday . The company traded as high as $15.24 and last traded at $15.3970. 473,161 shares were traded during trading, a decline of 90% from the average daily volume of 4,979,744 shares. The stock had previously closed at $14.63.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on the stock. BMO Capital Markets upgraded shares of Replimune Group from an "underperform" rating to an "outperform" rating and set a $16.00 target price for the company in a research report on Tuesday, June 30th. Wall Street Zen raised shares of Replimune Group from a "strong sell" rating to a "sell" rating in a report on Saturday, May 23rd. JPMorgan Chase & Co. boosted their target price on Replimune Group from $17.00 to $20.00 and gave the stock an "overweight" rating in a report on Friday, August 7th. Piper Sandler upgraded Replimune Group from a "hold" rating to a "strong-buy" rating in a research report on Friday, July 31st. Finally, Wedbush raised Replimune Group from a "neutral" rating to an "outperform" rating and set a $12.00 price target for the company in a report on Friday, August 7th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $11.86.

Replimune Group Trading Up 5.1%

The company has a quick ratio of 4.79, a current ratio of 4.79 and a debt-to-equity ratio of 0.63. The business's fifty day moving average is $10.77 and its two-hundred day moving average is $7.84. The firm has a market cap of $1.29 billion, a price-to-earnings ratio of -4.88 and a beta of 0.88.

Replimune Group (NASDAQ:REPL - Get Free Report) last announced its quarterly earnings data on Friday, August 14th. The company reported ($0.72) EPS for the quarter, missing analysts' consensus estimates of ($0.69) by ($0.03). Equities analysts anticipate that Replimune Group, Inc. will post -2.7 earnings per share for the current fiscal year.

Insider Activity

In related news, CAO Andrew Schwendenman sold 7,632 shares of the business's stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $12.97, for a total transaction of $98,987.04. Following the completion of the sale, the chief accounting officer directly owned 99,425 shares of the company's stock, valued at $1,289,542.25. The trade was a 7.13% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Christopher Sarchi sold 12,000 shares of the business's stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $9.24, for a total transaction of $110,880.00. Following the sale, the insider directly owned 180,962 shares of the company's stock, valued at approximately $1,672,088.88. This trade represents a 6.22% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 81,868 shares of company stock worth $1,017,068. Corporate insiders own 5.40% of the company's stock.

Institutional Trading of Replimune Group

Institutional investors have recently bought and sold shares of the business. ProShare Advisors LLC boosted its position in shares of Replimune Group by 10.3% in the 4th quarter. ProShare Advisors LLC now owns 16,116 shares of the company's stock worth $157,000 after purchasing an additional 1,505 shares during the last quarter. JPMorgan Chase & Co. grew its position in shares of Replimune Group by 4.7% during the 3rd quarter. JPMorgan Chase & Co. now owns 38,016 shares of the company's stock worth $159,000 after buying an additional 1,712 shares during the period. Ballentine Partners LLC grew its position in shares of Replimune Group by 7.8% during the 4th quarter. Ballentine Partners LLC now owns 23,665 shares of the company's stock worth $230,000 after buying an additional 1,721 shares during the period. BNP Paribas Financial Markets increased its stake in shares of Replimune Group by 37.5% in the 2nd quarter. BNP Paribas Financial Markets now owns 6,889 shares of the company's stock valued at $64,000 after acquiring an additional 1,879 shares during the last quarter. Finally, Walleye Capital LLC raised its position in shares of Replimune Group by 3.2% in the 1st quarter. Walleye Capital LLC now owns 71,592 shares of the company's stock valued at $548,000 after acquiring an additional 2,192 shares during the period. Institutional investors and hedge funds own 92.53% of the company's stock.

About Replimune Group

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company's proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune's lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source